Sign in

You're signed outSign in or to get full access.

Nabil Nassar

Senior Equity Research Analyst at Jefferies Financial Group Inc

Nabil Nassar is a Senior Equity Research Analyst at Jefferies Financial Group Inc., specializing in biotechnology and therapeutics research. He covers companies such as CytomX Therapeutics and Akebia Therapeutics, actively participating in earnings calls to analyze their strategies and clinical developments. Nassar is FINRA-registered as a broker with Jefferies LLC in Boston, though specific performance metrics like success rates or rankings are not publicly detailed in available records.

Nabil Nassar's questions to Akebia Therapeutics (AKBA) leadership

Question · Q4 2025

Nabil Nassar inquired about the trending of second and third Vafseo refill rates, comments on anemia manager education, and how the AKB-9090 asset is mechanistically differentiated from prior HIFs.

Answer

Chief Commercial Officer Nicholas Grund reported that first refill adherence improved from 75% historically to 91% in Q4 2025 for a small subset, and 87% in January for a larger observed dosing group. He noted significant continuation of adherence through the second prescription, with a 2-4% monthly discontinuation rate due to comorbidities. President, CEO, and Director John Butler added that physician belief in Vafseo's clinical benefit helps patients work through transient GI issues. John Butler and Nicholas Grund also discussed expanding the medical affairs group (MSLs) for education and DaVita's centralized anemia management model. Senior Vice President, Chief Research and Development Officer Steven K. Burke explained that AKB-9090 has different pharmacokinetics and a more widespread tissue penetration (lung, kidney) compared to vadadustat's liver preference, making it more suitable for ischemia-reperfusion injury.

Ask follow-up questions

Fintool

Fintool can predict Akebia Therapeutics logo AKBA's earnings beat/miss a week before the call